ReviewJournal of fungi (Basel, Switzerland)2016
New Horizons in Antifungal Therapy.
Review in Journal of fungi (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 188 citations in OpenAlex.
- Antifungal mechanism against Candida albicans and antitumor activity of phenazines produced by Pseudomonas sp. strain DH.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Targeting Fructosamine Oxidase (Amadoriase II) inCurrent medicinal chemistry · 2026Article
- Enhancing Solubility of a BCS Class II Drug- Itraconazole by Developing and Optimizing Solid Lipid Nanoparticles using a Central Composite Design.Pharmaceutical nanotechnology · 2026Article
- A biocompatible propolis pollen and ZnO nanorod composite with antimicrobial and antibiofilm activity.Scientific reports · 2025Article
- Review
- New Therapeutic Options for Fusariosis: A Patent Review (2008-2023).Journal of fungi (Basel, Switzerland) · 2025Article
- Synergistic effect of synthetic derivatives of 1,3,4-thiadiazole with amphotericin B in antifungal therapy.Scientific reports · 2025Article
- Development of a novel family of antifungal agents based on a quinone methide oxime framework.Scientific reports · 2025Article
- The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases.Discover nano · 2025Review
- Article
- Structures of trehalose-6-phosphate synthase, Tps1, from the fungal pathogenProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Humans vs. Fungi: An Overview of Fungal Pathogens against Humans.Pathogens (Basel, Switzerland) · 2024Review
- Exploring the antifungal, antibiofilm and antienzymatic potential of Rottlerin in an in vitro and in vivo approach.Scientific reports · 2024Article
- New insides into chimeric and hybrid azines derivatives with antifungal activity.Future medicinal chemistry · 2024Review
- Accelerating the understanding ofCurrent research in microbial sciences · 2024Review
- A heterologous expression platform inChemical science · 2023Article
- A Critical Review on the Dosing and Safety of Antifungals Used in Exotic Avian and Reptile Species.Journal of fungi (Basel, Switzerland) · 2023Review
- Synthesis of TiONanomaterials (Basel, Switzerland) · 2023Article
- Cyanobacteria: A Promising Source of Antifungal Metabolites.Marine drugs · 2023Review
- Identification of the Neoaspergillic Acid Biosynthesis Gene Cluster by Establishing anACS omega · 2023Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Recent investigations have yielded both profound insights into the mechanisms required by pathogenic fungi for virulence within the human host, as well as novel potential targets for antifungal therapeutics. Some of these studies have resulted in the identification of novel compounds that act against these pathways and also demonstrate potent antifungal activity. However, considerable effort is required to move from pre-clinical compound testing to true clinical trials, a necessary step toward ultimately bringing new drugs to market. The rising incidence of invasive fungal infections mandates continued efforts to identify new strategies for antifungal therapy. Moreover, these life-threatening infections often occur in our most vulnerable patient populations. In addition to finding completely novel antifungal compounds, there is also a renewed effort to redirect existing drugs for use as antifungal agents. Several recent screens have identified potent antifungal activity in compounds previously indicated for other uses in humans. Together, the combined efforts of academic investigators and the pharmaceutical industry is resulting in exciting new possibilities for the treatment of invasive fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.